Molecular Determinants of Coronaruy Artery Disease

NCT ID: NCT00590291

Last Updated: 2021-05-17

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 1461 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 1995-01-31
• Study Completion Date: 2021-04-01

Brief Summary

The purpose of this study is to discover genes that may cause Coronary Artery Disease (CAD) or Arteriovenous Malformation (AVM).

Detailed Description

The purpose of this study is to discover genes that may cause Coronary Artery Disease (CAD) or Arteriovenous Malformation (AVM). Many human diseases are inherited or passed from parent to child in families. These diseases occur because of damage to a gene(s), the genetic material that is also called DNA. Scientists can now use modern molecular techniques to locate and to find certain genes within the DNA (genetic material) of a person, and to follow their inheritance in a family. To find these disease-causing genes requires studies of many affected with the disease and their family members. The purpose of this study is to locate and to find the genes for coronary artery disease (CAD) which occurs when one or more of the arteries that carry oxygen-rich blood from your heart to the rest of your body develop blockages; or, arteriovenous malformation (AVM) which causes abnormal vascular connections between arteries and veins, particularly near the heart. Findings of the genes causing CAD and AVM will have far-reaching effect on the diagnosis, treatment, and prevention of coronary artery disease and arteriovenous malformation. These studies will lead to possible genetic diagnosis, early detection of persons at risk for developing CAD or AVM (even in the absence of symptoms), development of effective drugs, more rational and specific therapeutic interventions, treatments and ultimately, prevention of coronary heart disease. Approximately 3-5 years are required to find one human disease gene.

Conditions

Coronary Artery Disease; Arteriovenous Malformations; Myocardial Infarction

Study Design

• Observational Model Type: FAMILY_BASED
• Study Time Perspective: RETROSPECTIVE

Study Groups

Cases

premature CAD and MI, AVM

No interventions assigned to this group

Controls

No CAD, MI, AVM

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Males at least 45 years old and premenopausal females at least 50 years old at the time of onset of any of the following:
• PTCA
• MI
• CABG
• Must have a living sibling meeting the same criteria.

Exclusion Criteria

• Substance Abuse in the absence of angiographic coronary stenosis
• Congenital Heart Disease

• Minimum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

John Barnard

OTHER

Sponsor Role: lead

Responsible Party

John Barnard

PI

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

John Barnard, PhD

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Locations

Cleveland Clinic

Cleveland, Ohio, United States

Countries

United States

Other Identifiers

IRB4333

Identifier Type: OTHER

Identifier Source: secondary_id

1R01HL121358

Identifier Type: NIH

Identifier Source: secondary_id

View Link

GeneQuest

Identifier Type: -

Identifier Source: org_study_id